comparemela.com

Latest Breaking News On - Chronic kidney disease outcomes - Page 1 : comparemela.com

Severity of CKD-associated pruritus linked to all-cause mortality, other comorbidities

Severity of CKD-associated pruritus linked to all-cause mortality, other comorbidities
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesJennifers schererSchool of medicineChronic kidney disease outcomesPractice patterns study

Albuminuria reduction accounts for much of finerenone effect on CKD

Albuminuria reduction accounts for much of finerenone effect on CKD
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Rajiv agarwalIndiana university in indianapolisIndiana universityFinerenone induced albuminuria reductionChronic kidney disease outcomesInternal medicine

Study: Men More Likely Than Women to Start Dialysis

Recent study findings could explain the preponderance of men in the dialysis population.

United statesKidney internationalUniversity of viennaMedical universityChronic kidney disease outcomesPractice patterns study

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno,.

United kingdomUnited statesSouth africaOrenburgskaya oblastNew zealandArkhangel skaya oblastSouth koreaSteven bennerIndianj anaesthKenji yasukawaEnrique conternoMark eisnerJonathan barrattFibrogen incNational institute of diabetesUniversity of leicester

Astellas Receives European Commission Approval for

Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia.

United kingdomUnited statesSouth africaNew zealandOrenburgskaya oblastSouth koreaMichael tungSteven bennerAnna ottenKenji yasukawaEnrique conternoMark eisnerJonathan barrattFibrogen incUniversity of leicesterEuropean commission

vimarsana © 2020. All Rights Reserved.